Recommended Seasonal Influenza Vaccines for Different Age Groups: United States, 2016–2017 Influenza Season

VaccineTrade NameManufacturerPresentationThimerosal Mercury Content, μg Hg/0.5-mL doseAge Group
 IIV3Fluzone High-DoseSanofi Pasteur0.5-mL prefilled syringe0≥65 years
 IIV3FluvirinSeqirus0.5-mL prefilled syringe≤1.0≥4 years
5.0-mL multidose vial25≥4 years
 IIV3AfluriaSeqirus0.5-mL prefilled syringe0≥9 yearsa
5.0-mL multidose vial24.5≥9 yearsa via needle/syringe 18–64 years via jet injector
 aIIV3FluadSeqirus0.5-mL prefilled syringe0≥65 years
 ccIIV4FlucelvaxSeqirus0.5-mL prefilled syringe0≥4 years
 IIV4FluzoneSanofi Pasteur0.25-mL prefilled syringe06–35 months
0.5-mL prefilled syringe0≥36 months
0.5-mL vial0≥36 months
5.0-mL multidose vial25≥6 months
 IIV4Fluzone IntradermalSanofi Pasteur0.1-mL prefilled microinjection018–64 years
 IIV4FluarixGlaxoSmithKline0.5-mL prefilled syringe0≥3 years
 IIV4FluLavalID Biomedical Corporation of Quebec (distributed by GlaxoSmithKline)0.5-mL prefilled syringe0≥3 years
5.0-mL multidose vial<25≥3 years
 RIV3FlublokProtein Sciences0.5-mL vial0≥18 years
  • Sources: AAP Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2015–2016. Pediatrics. 2015;136(4):792–808; Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)—United States, 2016-2017 influenza season. MMWR Recomm Rep. 2016;65(RR-3):1-54. Implementation guidance on supply, pricing, payment, Current Procedural Terminology (CPT) coding, and liability issues can be found at aIIV, adjuvanted inactivated influenza vaccine.

  • a Age indication per the package insert is ≥5 years; however, the Advisory Committee on Immunization Practices recommends Afluria not be used in children 6 months through 8 years of age because of increased reports of febrile reactions noted in this age group. If no other age-appropriate, licensed inactivated seasonal influenza vaccine is available for a child 5 through 8 years of age who has a medical condition that increases the child’s risk of influenza complications, Afluria can be used; however, pediatricians should discuss with the parents or caregivers the benefits and risks of influenza vaccination with Afluria before administering this vaccine.